Blockchain in healthcare for traceability and data integrity

Healthcare is built over time. A consultation produces observations, diagnoses and prescriptions; a laboratory adds results; a pharmacy dispenses medicine; a hospital records procedures; and a payer checks coverage and billing. Each organization holds part of the episode under different duties. The patient moves across the system, but their information does not always travel with the same continuity.

Those records are not interchangeable documents. The clinical record informs care; a prescription authorizes dispensing; consent limits particular uses; an invoice starts an economic process; and an audit trail reconstructs who accessed or changed information. The legally authoritative source depends on the process and the institution responsible for it.

The problem is not a lack of databases. It is coordinating organizations with different systems, identifiers, formats and liabilities without losing context or confidentiality. Blockchain is relevant only where several parties must verify the same event and no central database provides suitable governance on its own. It does not replace the clinical record, medical judgement or interoperability standards.

In healthcare, blockchain works mainly as a layer of integrity and traceability, not tokenization. Instead of putting the asset on-chain, it anchors a verifiable fingerprint of each event. That event may be a medicine batch changing hands or a new version of a clinical record.

Sensitive patient data is not stored on the chain, but off it. On-chain there is only the cryptographic proof that lets anyone check nothing has been altered. That reconciles immutability with data protection.

A hash can confirm that a file is exactly the version previously recorded. If a number, image or character changes, the fingerprint no longer matches. This is useful for versioned clinical records, consent, laboratory results or trial documents because it exposes later alteration and can prove when a particular version existed.

The proof has a fundamental limit. It protects integrity from registration onwards, not the quality of the source data. A poorly calibrated measurement, mistaken identity or incorrectly coded diagnosis can be anchored with perfect immutability. Clinical controls, validated devices, identification, signatures and correction procedures remain necessary before an event is recorded.

Publishing a fingerprint is also insufficient without preserving the original evidence and its context. The institution must retrieve the document, establish who issued it, explain its meaning and associate it with the correct patient. In a mature architecture, blockchain provides sealing, sequence and shared verifiability; clinical repositories retain content, permissions, retention and rectification.

Blockchain provides a common evidence layer when hospitals, laboratories, pharmacies, insurers and manufacturers need to verify the same event across different systems. The network preserves shared states or fingerprints while each organization keeps clinical data under its own controls. The value lies in integrity, provenance and coordination across participants.

Traditional infrastructure gives every organization its own record and resolves discrepancies through messages, copies and reconciliation. A blockchain network lets authorized participants verify the same state and its history of changes. Personal data remains off-chain, while the shared proof reduces the need to replicate sensitive clinical information across counterparties.

Healthcare interoperability has several layers. Systems must connect, identify the patient and professional, interpret the same clinical concept and use it within an authorized process. Blockchain can provide a shared record of events or permissions, but it does not define what an allergy means, how an observation is coded or which fields make up a report.

Dedicated standards and frameworks supply that semantics. FHIR supports exchange through resources and APIs; terminologies such as SNOMED CT, LOINC and ICD normalize concepts; and national or regional profiles determine required elements. In the United States, USCDI and TEFCA form part of the exchange infrastructure. In the European Union, the EHDS introduces rules, interoperability components and phased implementation for primary and secondary uses of health data.

A DLT network adds value only when it integrates with those mechanisms. It can record consent, provenance, version or access and let organizations verify the event. The clinical document still travels through authorized channels in an intelligible format. If participants write incompatible data, the result is merely a distributed record of information that nobody can safely reuse.

In 2017, WHO estimated that close to one in ten medicines in low- and middle-income countries was falsified or substandard. Another study, published in 2020, attributed 34.2% of analysed US health expenditure for 2017 to administration. These figures have different scopes and do not measure the savings blockchain would produce.

In Europe, the medicines verification system checks identifiers and raises alerts about suspicious packs within the legal supply chain. Estonia uses KSI to protect the integrity of health records and access logs while retaining clinical data in its healthcare infrastructure. e-Estonia reports 2.7 million monthly patient queries, a measure of portal usage rather than blockchain transactions.

Most deployments are permissioned networks between institutions, with personal data kept off-chain. The value lies in verifiable provenance and data integrity, not in tokenizing health.

A clinical trial produces protocols, consent records, allocations, observations, images, analyses and document changes over several years. Sponsors, sites, investigators, laboratories, CROs and regulators must reconstruct which version applied, who entered each datum and which correction followed. A shared sealing layer can reduce disputes over sequence and provenance.

That does not make a public blockchain an appropriate research repository. Participant data, randomization codes and information that could break blinding require strict controls. Even a hash may be personal data when it can be used to relate or verify information about a person. The design must minimize publication, avoid reusable identifiers and assess whether a permissioned network adds anything beyond a conventional audit log.

Secondary use raises another issue. Technical availability does not establish lawful reuse. Consent, legal basis, ethics review, access permission and data-space conditions determine legitimacy. Blockchain can record those authorizations and their evolution, but governance decides who evaluates a request, which secure environment is used and how reidentification is prevented.

The strongest use cases share one condition. Several organizations must verify the same event, yet none needs to publish the full record. Pharmaceutical traceability, document integrity, professional credentials and permission coordination fit when identity is reliable, the data source is governed and responsibility for every declaration remains clearly assigned.

Automation is strongest when an event is objective, well coded and all parties accept the source. Confirmation that a serialized medicine was dispensed, a professional credential remains valid or a complete document was received can trigger the next step. The contract reduces waiting and reconciliation because everyone observes the same state.

Many healthcare claims do not meet those conditions. Coverage may depend on medical necessity, exclusions, prior authorization, coordination between payers or document review. A correct code alone does not prove that treatment was indicated. Automation without an exception path moves the error onto the patient and can turn a data inconsistency into an immediate denial.

Sound design separates deterministic decisions from those requiring review. A contract may check requirements, reserve funds, detect duplicates and record milestones; a professional or regulated procedure resolves disputes and authorizes exceptions. There must also be a way to correct the source and rerun the process without erasing its history. The aim is to reduce repetitive work, not hide healthcare policy inside code.

Architecture separates shared proof from clinical content. On-chain records hold minimal identifiers, states, signatures or fingerprints that several entities must verify. Records, images, consents and documents remain in governed repositories where they can be corrected, restricted or deleted. This separation limits exposure, although it does not remove reidentification risk by itself.

A fingerprint, public key or transaction pattern may still be personal data when it can single out or link a person. Risk increases when the same identifier is reused across hospitals, pharmacies and insurers. Avoiding a patient's name on-chain prevents the most obvious mistake, but it does not remove inference risk or data-protection duties.

The controller must define purpose, legal basis, minimization, retention and recipients before choosing the architecture. It must also determine who operates nodes, who can read metadata, where keys and repositories are held and how access, rectification, objection or erasure are handled. EDPB blockchain guidance specifically emphasizes identifying roles and applying data protection by design.

Key management is particularly sensitive. Loss of a key cannot exclude a patient from care; a compromised key must be rotated without destroying legitimate traceability. Healthcare identity therefore rarely rests on a self-custodied wallet as the sole mechanism. Recoverable credentials, delegation, institutional authentication and access logs must coexist with conventional security and continuity procedures.

A production healthcare solution is usually hybrid. Clinical and pharmaceutical systems retain content; identity services link organizations and professionals; an interoperability layer translates messages and terminologies; and the distributed ledger stores events, proofs or states requiring shared verification. Nodes do not replace those components.

Network governance must assign operational responsibility. Someone onboards participants, upgrades software, responds to vulnerabilities, defines consensus and resolves a fork or disputed datum. A permissioned network can distribute validation among institutions, but it still needs contractual authority and change procedures. Distributing infrastructure does not remove healthcare accountability.

Availability also matters. An emergency, connectivity failure or unavailable node cannot block access to critical information. Systems need degraded operation, secure queues and later reconciliation. The clinical purpose determines service levels, not the chain's theoretical characteristics. The closer a network sits to a care decision, the stronger its recovery and oversight must be.

A referral between providers offers a concrete integration test. The sending centre shares the authorised report, and the recipient checks origin, version and permissions before introducing it into the clinical workflow. A later correction should arrive as a linked version so that clinicians can distinguish the initial document from the current one. Testing should also cover duplicate identities and misassigned documents. A matching fingerprint does not by itself establish that two records concern the same patient or that a report belongs in the receiving record.

Access logs need a clear purpose and proportionate handling. They can support investigation of inappropriate access while also revealing care relationships. Permissions should distinguish treatment, administration, research and audit, with specific procedures when purpose changes. Emergency operation must be defined by the healthcare organisation and preserve evidence of actions taken. The technical infrastructure implements that design without turning network unavailability into an automatic clinical decision. Acceptance should involve clinical and information-governance staff alongside the engineers responsible for integration.

Drug traceability is regulated. The US requires it through the DSCSA, with interoperable exchange based on the GS1 standard, and the EU through the Falsified Medicines Directive and its verification system. Any traceability solution must fit those systems while preserving the responsibilities of manufacturers, distributors and dispensers.

For clinical data, GDPR requires purpose, legal basis, minimization, retention, roles and data-subject rights to be defined before architecture. Keeping content off-chain reduces exposure, but a fingerprint or its metadata may still be personal data when linkable. The design must assess that risk rather than assume a hash falls outside the rules.

A useful pilot starts with a bounded problem among identified organizations. It may verify a credential, coordinate a recall, prove document versions or reduce a specific reconciliation. Before building, it measures current time, error rate, dispute cost and who bears each responsibility. Without a baseline, a technical demonstration cannot establish improvement.

Success is not measured in on-chain transactions either. Traceability metrics include event completeness, time to locate a batch and the ability to investigate an anomaly. Clinical exchange metrics include correct identity, usefulness of received data and fewer duplicates. Claims metrics include resolution time, exceptions and overturned decisions. Each measure must reflect a healthcare or operating outcome.

Scaling means accommodating smaller participants, legacy systems and exceptional situations. If the model requires bespoke integration for large institutions alone, it may create another technology island. The final decision compares a distributed network with governed APIs, electronic signatures, shared repositories or timestamping services. Blockchain should remain only when it distributes trust and control in a way those alternatives cannot achieve with less complexity.

A shared record can strengthen evidence and coordination, but it does not by itself improve quality of care or correct the incentives, inequalities and process errors feeding the network. It also cannot replace semantic interoperability, clinical judgement, device security or professional responsibility for decisions made from the information received.

These concepts separate the evidence infrastructure, the systems holding clinical data and the rules authorizing its use. They help assess proposals without confusing integrity with quality, access with consent or technical exchange with organizational interoperability. They also explain why a cryptographic fingerprint may still remain linked to personal data.